Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: Implications for warfarin management in hispanics

Ethnicity and Disease

Volumn 19, Issue 4, 2009, Pages 390-395

  Duconge, Jorge ^a   Cadilla, Carmen L ^b   Windemuth, Andreas ^c   Kocherla, Mohan ^c   Gorowski, Krystyna ^c   Seip, Richard L ^c   Bogaard, Kali ^c   Renta, Jessica Y ^b   Piovanetti, Paola ^b   D'Agostino, Darrin ^d   Santiago Borrero, Pedro J ^a   Ruaño, Gualberto ^c  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c Hartford Hospital ^*  (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

CYP2C9; Genotyping; Personalized medicine; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE DETECTION; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PUERTO RICO; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; EPIDEMIOLOGY; GENETICS; METABOLISM; METAGENOMICS;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; GENOTYPE; HUMANS; METAGENOMICS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PUERTO RICO; SEROEPIDEMIOLOGIC STUDIES; WARFARIN;

EID: 77949324338     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lakshminarayan K, Solid CA, Collins AJ, et al. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992-2002). Stroke. 2006;37:1969-1974.
2. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:204S-2033S. (Pubitemid 39297955)
3. The top 200 generic drugs in 2007 (by units). Drug Topics. 2008;152:156.
4. The top 200 brand drugs in 2007 (by units). Drug Topics. 2008;152:154.
5. Couris R, Tataronis G, McCloskey W, et al. Dietary vitamin K variability affects International Normalized Ratio coagulation indices. Int J Vitam Nutr Res. 2006;76:65-74. (Pubitemid 44367102)
6. Hylek EM. Oral anticoagulants: Pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001;17:1-13.
7. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36: 1512-1517.
8. Linder MW, Looney S, Adams JE, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002;14:227-232. (Pubitemid 37069306)
9. ScordoMG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72:702-710. (Pubitemid 36021009)
10. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106: 2329-2333
11. Kamali F, Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol. 2006;61:746-751 (Pubitemid 43794805)
12. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39-42.
13. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005;93:700-705. (Pubitemid 40485406)
14. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-1698.
15. Reynolds KK, Valdes JrR, Hartung BR, Linder MW. Individualizing warfarin therapy. Personalized Medicine. 2007;4:11-31.
16. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007;53: 1199-1205 (Pubitemid 47020974)
17. Wu AH. Use of genetic and non-genetic factors in warfarin dosing algorithms. Pharmacogenomics. 2007;8:851-861.
18. Mushiroda T, Ohnishi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet. 2006;51: 249-253
19. Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 2004;4:40-48. (Pubitemid 38256604)
20. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5:262-270 (Pubitemid 41131718)
21. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007;121:23-34. (Pubitemid 46421137)
22. Hillman MA, Wilke RA, Caldwell MD, et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics. 2004;14:539-547.
23. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-541 (Pubitemid 38209110)
24. Li T, Chang CY, Jin DY, et al. Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541-544
25. Suttie JW. The biochemical basis of warfarin therapy. Adv Exp Med Biol. 1987;214: 3-16.
26. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-1751.
27. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-2293.
28. Bristol-Myers Squibb Pharma Company. Princeton, NJ. Coumadin Label. Available at: http://www.fda.gov/cder/foi/label/2007/009218s105lblv2.pdf. Last accessed: August, 2007.
29. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893-900.
30. McWilliam A, Lutter R, Nardinelli C. Health care savings from personalized medicine using genetic testing: the case of warfarin. Working Paper. AE1-Brookings Joint Center for Regulatory Studies. 2006. Available at: http://www.reg-markets.org/publications/index.php?tab=author&authorid=5. Last accessed: August 11, 2009.
31. Rosenberg Y. Rationale and outline of an NHLB/NIH Initiative for a large, multicenter randomized trial of genotype-guided dosage of warfarin therapy. Slide presentation; NHLB/NIH workshop. 2006.
32. Gordon J, Merante F, Weiss S, Zastawny R. Pharmacogenetic P-450 screening using the Tag-It universal bead-based array platform. In: Wong SH, Linder MW, Valdes R, eds. Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. Washington, DC: AAC Press, 2006.
33. Ruano G, Thompson PD, Bower B, et al. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. Personalized Medicine. 2008;5:225-232. (Pubitemid 351824565)
34. Salari K, Choudhry S, Tang H, et al. Genetic admixture and asthma-related phenotypes in Mexican-American and Puerto Rican asthmatics. Genet Epidemiol. 2005;29:76-86. (Pubitemid 40911301)
35. Choudhry S, Coyle NE, Tang H, et al. Population stratification confounds genetic association studies among Latinos. Hum Genet. 2006;118:652-664. (Pubitemid 41825137)
36. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11:803-808. (Pubitemid 33151515)
37. Allabi AC, Gala JL, Desager JP, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003;56:653-657.
38. Tanira MO, Al-Mukhaini MK, Al Hinai AT, et al. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genet. 2007;10:32-37.
39. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006;80:13-22. (Pubitemid 43964915)
40. Schwarz UI, Stein CM. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther. 2006;80:7-12.
41. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/ T genotype on the risk of hemorrhagic complications in African-American and European- American patients on warfarin. Clin Pharmacol Ther. 2007;83:312-320
42. Veenstra DL, You JH, Rieder MJ, et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics. 2005;15:687-691
43. Cho HJ, Sohn KH, Park HM, et al. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics. 2007;8: 329-337
44. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2007;25: 45-51.
45. Womack C. As Part of Retrofitting, FDA Panel Votes to Re-label Warfarin for PGx; Is Dx Far Behind? Pharmacogenomics Reporter. 2005;12-1-0005.
46. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005;7:97-104. (Pubitemid 40261834)
47. Lindh JD, Lundgren S, Holm L, et al. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther. 2005;78:540-550. (Pubitemid 41698908)
48. Visser LE, van-Vliet M, van-Schaik RH, et al. The risk of overanticoagulation in patients with CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics. 2004;4:27-33.
49. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost. 2005;93:700-705. (Pubitemid 40485406)
50. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96:1816-1819 (Pubitemid 30661066)
51. Ruano G. Quo Vadis Personalized medicine? Personalized Medicine. 2004;1:1.